At the EuroPCR conference, scheduled to be held between May 15 and 18 in Paris, Boston Scientific Corporation (NYSE:BSX) will be presenting data from several of its clinical programs.
The company will be presenting data from the Evolve trial that evaluated the Synergy stent, the fourth-generation drug-eluting stent (“DES”). Boston Scientific is looking forward to approval of the stent in Europe in late 2012 with its full launch scheduled for 2013. The company also has plans to begin trial of … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here